| Literature DB >> 29051525 |
Fiorella Krapp1, Andrew R Morris2, Egon A Ozer3, Alan R Hauser3,4.
Abstract
Two types of Klebsiella pneumoniae (KP) strains are currently emerging: hypervirulent (hvKP) strains and carbapenem-resistant (CR-KP) strains. To date, these two strain types rarely overlap. Recent reports, however, suggest that CR-KP strains are increasing in virulence. hvKP strains frequently present as highly invasive infections, such as necrotizing skin and soft tissue infections (NSSTI). To examine whether CR-KP strains with features of hvKP were present in our U.S. hospital, we retrospectively identified four cases of CR-KP NSSTI diagnosed between January 2012 and January 2016. Whole-genome sequencing was used to perform multilocus sequence typing, capsular typing, and identification of virulence and antimicrobial resistance genes. Additionally, the virulence of each isolate was determined in vitro and using murine pneumonia and subcutaneous infection models. We identified one CR-KP isolate that possessed features of hypervirulent KP, including a hypermucoviscous phenotype, K2 capsule, and resistance to phagocytosis. Of the four CR-KP isolates, two had no evidence of enhanced pathogenicity in either mouse model, demonstrating that low-virulence strains can cause NSSTI in immunosuppressed patients. The remaining two isolates exhibited low virulence in the pneumonia model but high virulence in the subcutaneous infection model, suggesting that the virulence attributes of these isolates are adapted to causing NSSTI.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29051525 PMCID: PMC5648777 DOI: 10.1038/s41598-017-13524-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographics, clinical characteristics and outcomes of patients who presented with CR-KP NSSTI.
| NU-CRE101 | NU-CRE176 | NU-CRE212 | NU-CRE265 | |
|---|---|---|---|---|
| Clinical Characteristics | ||||
| Age, Sex | 69, M | 50, F | 46, M | 43, M |
| Charlson Score | 6 | 4 | 6 | 6 |
| Specific Comorbidities | Bladder cancer on chemotherapy | Myasthenia gravis on chronic corticosteroids | DM, CKD on dialysis, failed kidney and pancreas transplant on IS | DM, CKD on dialysis |
| Immunosuppresed | Yes | Yes | Yes | No |
| Community-acquired infection | No | Yes | No | No |
| Post-surgical Infection | No | No | Yes | Yes |
| Modified SOFA score | 2 | 4 | 7 | 4 |
| Fever/Hypotension | Yes/No | No/Yes | Yes/Yes | No/No |
| Microbiologic characteristics | ||||
| Culture source | Tissue | Tissue/Blood | Tissue | Tissue |
| Polymicrobial culture | VRE | No | MSSA | No |
| Meropenem Susceptibility | R (>16) | R (>16) | R (>16) | R (>16) |
| Management | ||||
| Source control achieved (surgery) | Yes | Yes | Yes | Yes |
| Time to effective antibiotic (hs) | 39.8 | 80.7 | 70.8 | 131.1 |
| Duration of effective antibiotic (days) | 19 | unknowna | 28 | unknownb |
| Outcomes | ||||
| Length of hospital stay (days) | 23 | 6 (transferred) | 13 | 55 |
| In-hospital death | survived | survived | survived | survived |
| Relapse | No | after 5 months | after 4 months | No |
| Overall death (post-discharge) |
|
| No | No |
| Death attributable to infection | No |
| No | No |
DM, diabetes mellitus; CKD, chronic kidney disease; IS, Immunos supressants; VRE, vancomycin-resistant Enterococcus spp.; MSSA, methicillin-susceptible Staphylococcus aureus.
aTotal duration of effective antibiotic treatment is unknown, because the patient was transferred to another facility after 6 days of treatment.
bTotal duration of effective antibiotic treatment is unknown, because the patient was transferred to a rehabilitation facility and had no follow up at our institution.
Hypermucoviscosity and genomic characterization of CR-KP isolates associated with NSSTI.
| NTUH-2044 | MGH78578 | NU-CRE101 | NU-CRE176 | NU-CRE212 | NU-CRE265 | |
|---|---|---|---|---|---|---|
| String test | + | − | − | − | − | + |
| MLST | ST23 | ST38 | ST1082 | ST258 | ST258 | ST14 |
| Capsule Serotype | K1 | K52 | K51 | non-typable | non-typable | K2 |
| Virulence factors | ||||||
| Capsule up-regulation | ||||||
| rmpA | + | − | − | − | − | − |
| rmpA2 | + | − | − | − | − | − |
| Siderophore systems | ||||||
| Enterobactin ( | + | + | + | + | + | + |
| Aerobactin ( | + | − | − | − | − | − |
| Aerobactin receptor ( | + | + | + | + | + | + |
| Yersiniabactin ( | + | − | − | + | + | − |
| Yersiniabactin receptor ( | + | − | − | + | + | − |
| Salmochelin ( | + | − | − | − | − | − |
| Salmochelin receptor (i | + | + | + | + | + | + |
| Genotoxin | ||||||
| Colibactin ( | − | − | − | + | + | − |
| Fimbrial genes | ||||||
| Type 3 fimbrial adhesion genes | + | + | + | + | + | + |
| Type 1 fimbrial adhesion genes | + | + | + | + | + | + |
| Other genes | ||||||
| | + | − | + | − | − | + |
| | + | − | − | − | − | − |
| Antibiotic resistance genes | ||||||
| Beta-lactamases | SHV-11 | SHV-11 | KPC-2 | KPC-3 | KPC-3 | KPC-3 |
| SHV-1 | SHV-11 | SHV-11 | SHV-28 | |||
| TEM-1 | TEM-1A | OXA-9 | ||||
| OXA-9 | ||||||
| Aminoglycosides resistance genes | − | − |
|
|
|
|
|
|
|
|
| |||
| aacA4 |
|
|
| |||
| Fluoroquinolones resistance genes |
|
|
|
|
|
|
|
|
|
|
| |||
| Other resistance genes |
|
|
|
|
|
|
|
|
|
|
| |||
MLST, multilocus sequence typing. “+” indicates that gene was present, “−” indicates that gene was absent.
*A complete list of the genes involved in the synthesis of these virulence factors can be found in the Supplementary Figure S1.
Figure 1Capsule quantification of CR-KP NSSTI isolates. CPS production was analyzed from equivalent amounts of overnight KP cultures. Total CPS levels were determined by measuring absorbance at 520 nm and normalized to the total viable bacteria (micrograms uronic acid/106 CFU). Data are expressed as means ± SEM. p values were derived from comparisons of each strain to MGH78578 via one-way ANOVA with Bonferroni’s multiple comparison correction (*P ≤ 0.05). Samples were measured in triplicate, and data are representative of three independent experiments.
Figure 2Uptake of CR-KP NSSTI isolates by murine macrophage-like cells. KP strains were incubated with the murine macrophage-like cell line J774.A1 at an MOI of 10. At 1 h post-infection, amikacin was added to the medium, and cells were incubated for 1 h to eradicate extracellular bacteria. The number of intracellular bacteria was then measured by lysing the eukaryotic cells and plating for viable CFUs. The results are expressed as a percentage of the inoculum, and the means and standard deviations are indicated. p values were derived from comparisons of each group to the MGH78578 group via one-way ANOVA with Bonferroni’s multiple comparison correction (*P < 0.05). Each symbol represents the mean of an assay performed in triplicate. Results were combined from three independent experiments.
Figure 3Virulence of CR-KP NSSTI isolates in a mouse model of acute pneumonia. Bacterial burdens within the lungs and livers of C57BL/6 mice intranasally infected with either 5 × 106 (A) or 5 × 107 (B) CFU of the indicated KP strains were measured. For the highly virulent NTUH-K2044 strain, the inoculum was decreased to 1 × 103 CFU to allow survival out to 96 h post-infection. Organs were harvested and the total viable CFU determined at 96 h post-infection. Each symbol represents the bacterial numbers recovered from a single mouse. Solid bars denote the median CFU, and the dashed line indicates the limit of detection (100 CFU). p values were derived from the comparisons of each group to the MGH78578 infected group (Mann-Whitney U test; *P ≤ 0.05). Data are combined from at least 2 independent experiments (n = 7 for each group).
Figure 4Virulence of CR-KP NSSTI isolates in a subcutaneous infection model. C57BL/6 mice were infected subcutaneously with approximately 5 × 106 CFU of the indicated KP strains. (A) Abscess areas were measured up to 96 h post-infection. Data are expressed as means ± SEM. p values were derived from comparisons of each group to the MGH78578 infected group at specified time points (one-way ANOVA with Bonferroni’s multiple comparison correction; *p ≤ 0.05). Bacterial burdens in the abscess (B) and the livers (C) were determined at 96 h post-infection (hpi). Each symbol represents the bacterial CFU recovered from a single mouse. Solid bars denote the median CFU, and the dashed line indicates the limit of detection (100 CFU). p values were derived from the comparisons of each group to the MGH78578 infected group via the Mann-Whitney U test. *p ≤ 0.05. Data are combined from 3 independent experiments (n = 9 for each group).
Figure 5Persistence and dissemination of CR-KP NSSTI isolates following neutrophil depletion in the subcutaneous infection model. C57BL/6 mice treated with either anti-ly6G antibody or IgG isotype control antibody were infected subcutaneously with approximately 5 × 106 CFU of the indicated KP strains. (A) Abscess areas were measured at 96 h post-infection. Data are expressed as means ± SEM. Bacterial burdens in the abscesses (B) and livers (C) were measured at 96 h post-infection. Each symbol represents the bacterial numbers recovered from a single mouse. Solid bars denote the median CFU, and the dashed line indicates the limit of detection (100 CFU). p values were derived from comparisons of each group of mice to the MGH78578 infected groups via one-way ANOVA with Bonferroni’s multiple comparison correction (abscess area) or the Mann-Whitney U test (CFU); *p ≤ 0.05 vs. IgG control group; +p ≤ 0.05 vs. Ly6G treated group. For comparisons within each strain, p values were derived via Student’s t test (#p ≤ 0.05). Data are combined from 3 independent experiments (n = 9 for each group).
Figure 6A capsule mutant of NU-CRE265 exhibits impaired virulence in the subcutaneous infection model. C57BL/6 mice treated with either anti-Ly6G antibody or IgG isotype control antibody were infected subcutaneously with approximately 5 × 106 CFU of NU-CRE265 or NU-CRE265Δcps. (A) Abscess areas were measured at 96 h post-infection. Data are expressed as means ± SEM. Bacterial burdens in the abscesses (B) and livers (C) were measured at 96 h post-infection. Each symbol represents the number of bacteria recovered from a single mouse. Solid bars denote the median CFU, and the dashed line indicates the limit of detection (100 CFU). *p ≤ 0.05; one-way ANOVA with Bonferroni’s multiple comparison correction (abscess area) or the Mann-Whitney U test (CFU). Data are combined from 2 independent experiments (n = 10 for each group).